RxDoctor Payments DataLook up a doctor →

Mary Knesevich

Psychiatry · Dallas, TXNPI 1033120811

Payments from drug & device makers

$1,201,468in general payments, 2019–2025

Across 183 payments — averaging $6565.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$316K
  • Boehringer Ingelheim$254K
  • Bioxcel Therapeutics, Inc.$165K
  • Roche TCRC, Inc.$145K
  • Supernus Pharmaceuticals, Inc.$128K
  • Teva Pharmaceuticals USA, Inc.$71K
  • plus $122K from 7 others
$523,968in research payments, 2019–2025

Across 70 payments — averaging $7485.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$252K
  • Teva Pharmaceuticals USA, Inc.$158K
  • Hoffmann-la Roche Limited$82K
  • Acadia Pharmaceuticals Inc$31K
  • Avanir Pharmaceuticals, Inc.$1K

General payments by program year

20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,201,468 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →